financetom
Business
financetom
/
Business
/
Nokia starts production of next generation 5G equipment in India
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nokia starts production of next generation 5G equipment in India
Dec 8, 2020 3:41 AM

Telecom gear maker Nokia on Tuesday said it has started production of 5G equipment in India and the equipment are being shipped to countries that are in advanced stages of deploying the next-generation technology. The roll-out of 5G services in India is dependent on spectrum auction as telecom operators need suitable wireless frequencies to start 5G in the country.

”From being the first to manufacture 5G NR in India to producing mMIMO, it demonstrates our innovative manufacturing capabilities and our belief in India’s skill and talent to produce the best-in-class equipment. This will enable us to support Indian Operators as they prepare to launch 5G,” Nokia Senior Vice President and Head of India Market Sanjay Malik said in a statement. Nokia was the first to manufacture the 5G New Radio in India, and it is now producing the cutting-edge Nokia AirScale massive Multiple Input Multiple Output (mMIMO) solution, the company said.

”Nokia Chennai factory is manufacturing the latest 5G massive MIMO equipment that is shipped to countries who are in advanced stages of 5G deployment. ”Since 2008, the site has manufactured over 5 million telecom network equipment units, exporting over 50 percent to more than 100 countries,” the statement said.

Nokia claims to have invested over Rs 600 crore since 2008 to develop the facility. ”Our Chennai factory has emerged as a benchmark of India’s manufacturing capabilities, bringing an entire range of telecom technology to operators in India and the rest of the world,” Malik said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Carlyle Group Pursues Sale of Cogentrix Energy
Market Chatter: Carlyle Group Pursues Sale of Cogentrix Energy
Jun 17, 2024
05:10 AM EDT, 06/17/2024 (MT Newswires) -- Carlyle Group ( CG ) is considering a sale of electric power company Cogentrix Energy, the Financial Times reported, citing unnamed people familiar with the matter. The private-equity firm is seeking to sell the company, which has stakes in 13 US natural gas power plants, at a valuation of as much as $3...
Analysis-Brazil joins race to loosen China's grip on rare earths industry
Analysis-Brazil joins race to loosen China's grip on rare earths industry
Jun 17, 2024
MELBOURNE/RIO DE JANEIRO (Reuters) - Mining giant Brazil has big ambitions to build a rare earths industry as Western economies push to secure the metals needed for magnets used in green energy and defence and break China's dominance of the supply chain. Working to its advantage are low labour costs, clean energy, established regulations and proximity to end markets, including...
China opens tit-for-tat anti-dumping probe into European pork
China opens tit-for-tat anti-dumping probe into European pork
Jun 17, 2024
BEIJING (Reuters) -China has opened an anti-dumping investigation into imported pork and its by-products from the European Union, a step that appears mainly targetted at Spain, the Netherlands, France and Denmark in response to curbs on its electric vehicle exports. The investigation announced by China's commerce ministry on Monday will focus on pork intended for human consumption, such as fresh,...
Regeneron Pharmaceuticals Says 50% of Patients in Multiple Myeloma Therapy Study Achieved Complete Response
Regeneron Pharmaceuticals Says 50% of Patients in Multiple Myeloma Therapy Study Achieved Complete Response
Jun 17, 2024
04:53 AM EDT, 06/17/2024 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) said Sunday long-term data from an early-to-mid-stage trial of its experimental therapy, linvoseltamab, showed that 50% of patients with relapsed/refractory multiple myeloma, a type of blood cancer, achieved a complete response while the overall response rate was 71%. The study compared linvoseltamab with real-world standard-of-care treatment in clinical...
Copyright 2023-2026 - www.financetom.com All Rights Reserved